var title_f14_38_14944="Contents: Colorectal surgery";
var content_f14_38_14944=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Colorectal surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Colorectal surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Appendicitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/40/31370\">",
"           Acute appendicitis in adults: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/7/5242\">",
"           Acute appendicitis in adults: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/3/32826\">",
"           Acute appendicitis in children: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/61/19416\">",
"           Acute appendicitis in children: Diagnostic imaging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/2/31785\">",
"           Acute appendicitis in children: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/34/42536\">",
"           Acute appendicitis in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bowel preparation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/39/27258\">",
"           Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/49/30489\">",
"           Overview of the management of primary colon cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Colon and rectal cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30586\">",
"           Adjuvant chemotherapy for resected stage II colon cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/51/11066\">",
"           Adjuvant therapy for resected colon cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/51/4922\">",
"           Adjuvant therapy for resected rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/44/34506\">",
"           Adjuvant therapy for resected stage III (node-positive) colon cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/59/19386\">",
"           Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/33/17946\">",
"           Clinical manifestations, diagnosis, and staging of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40342\">",
"           Colorectal cancer and primary sclerosing cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/7/25722\">",
"           Colorectal cancer surveillance in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/18/28967\">",
"           Endoscopic ultrasound in rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41850\">",
"           Management of potentially resectable colorectal cancer liver metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/33/30234\">",
"           Molecular genetics of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/22/42346\">",
"           Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/34/41514\">",
"           Pathology and prognostic determinants of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/57/6041\">",
"           Pretreatment local staging evaluation for rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/16/34057\">",
"           Surgical oncologic principles for resection of primary rectal adenocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/23/16762\">",
"           Surgical oncologic principles for the resection of colon cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/32/44554\">",
"           Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/20/21833\">",
"           Systemic chemotherapy for metastatic colorectal cancer: General principles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44058\">",
"           Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/51/30519\">",
"           Tattooing and other methods for localizing colonic lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/37/11866\">",
"           Treatment of locally advanced unresectable or recurrent rectal cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Colon and rectal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/34/25128\">",
"           Abdominal perineal resection (APR): Open technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/39/21113\">",
"           Abdominal surgical incisions: Prevention and treatment of complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/1/15384\">",
"           Anal fissure: Medical and surgical management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/25/12694\">",
"           Anorectal fistula: Clinical manifestations, diagnosis, and management principles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/29/34263\">",
"           Delayed surgical management of the disrupted anal sphincter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/3/25656\">",
"           Fast-track protocols in colorectal surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/61/26585\">",
"           Initial surgical management of melanoma of the skin and unusual sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/16/20744\">",
"           Left colectomy: Open technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/29/19930\">",
"           Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41850\">",
"           Management of potentially resectable colorectal cancer liver metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/29/38361\">",
"           Operative management of Crohn's disease of the small bowel and colon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/30/7655\">",
"           Overview of rectal procidentia (rectal prolapse)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/15/38137\">",
"           Overview of surgical procedures for resectable primary rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/49/30489\">",
"           Overview of the management of primary colon cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/33/2586\">",
"           Postoperative ileus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/57/6041\">",
"           Pretreatment local staging evaluation for rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26359\">",
"           Preventing postoperative peritoneal adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/23/28024\">",
"           Right and extended right colectomy: Open technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/54/41832\">",
"           Surgical approach to rectal procidentia (rectal prolapse)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/61/28634\">",
"           Surveillance after colorectal cancer resection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications of colorectal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/5/4186\">",
"           Management of anastomotic complications of colorectal surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/57/1946\">",
"           Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/30/4585\">",
"           Management of perineal complications following an abdominal perineal resection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diverticular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/52/42819\">",
"           Acute diverticulitis complicated by fistula formation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/6/34919\">",
"           Clinical manifestations and diagnosis of colonic diverticular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/49/38679\">",
"           Colonic diverticular bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/63/36854\">",
"           Epidemiology and pathophysiology of colonic diverticular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/8/13450\">",
"           Treatment of acute diverticulitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endoscopic ultrasound",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/14/21735\">",
"           Endorectal endoscopic ultrasound in the evaluation of fecal incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/18/28968\">",
"           Endoscopic removal of large colonic polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/18/28967\">",
"           Endoscopic ultrasound in rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/30/3561\">",
"           Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fissures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/24/34181\">",
"           Anal fissure: Clinical manifestations, diagnosis, prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/20/25928\">",
"           Lateral internal sphincterotomy for management of an anal fissure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fistulas",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/52/42819\">",
"           Acute diverticulitis complicated by fistula formation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/14/28903\">",
"           Clinical features, diagnosis, and prevention of pancreatic fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/51/5946\">",
"           Operative management of anorectal fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/40/26246\">",
"           Perianal abscess: Clinical manifestations, diagnosis, treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32951\">",
"           Rectovaginal, anovaginal, and colovesical fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/25/39319\">",
"           The role of imaging tests in the evaluation of anal abscesses and fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/47/44792\">",
"           Urogenital tract fistulas in women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal bleeding",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/63/8184\">",
"           Approach to minimal bright red bleeding per rectum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/7/30841\">",
"           Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/49/38679\">",
"           Colonic diverticular bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29513\">",
"           Diagnostic approach to lower gastrointestinal bleeding in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/33/1562\">",
"           Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36074\">",
"           Cancer of the appendix and pseudomyxoma peritonei",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12761\">",
"           Classification and epidemiology of anal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17754\">",
"           Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/48/35593\">",
"           Malignant peritoneal mesothelioma: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/48/15110\">",
"           Approach to the patient with anal pruritus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/62/32746\">",
"           Approach to the patient with colonic polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/12/9414\">",
"           Diversion colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/56/30601\">",
"           Pathophysiology of the short bowel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemorrhoids",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/28/19912\">",
"           Outpatient and surgical procedures for hemorrhoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/14/5348\">",
"           Overview of hemorrhoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/61/6105\">",
"           Treatment of hemorrhoids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inflammatory bowel disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/0/20490\">",
"           Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/7/11386\">",
"           Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/7/25722\">",
"           Colorectal cancer surveillance in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3319\">",
"           Management of severe ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/50/809\">",
"           Medical prophylaxis of postoperative Crohn's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/54/19305\">",
"           Overview of the medical management of mild to moderate Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/43/25273\">",
"           Perianal complications of Crohn's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/13/25818\">",
"           Restorative proctocolectomy with ileal pouch-anal anastomosis: Laparoscopic approach",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/24/41350\">",
"           Skin and eye manifestations of inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/50/4906\">",
"           Surgical management of ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/30/18920\">",
"           Toxic megacolon",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Obstruction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/50/22311\">",
"           Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/34/5673\">",
"           Enteral stents for the management of malignant colorectal obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39654\">",
"           Rectal foreign bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14058\">",
"           Small bowel obstruction: Causes and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/38/8807\">",
"           Small bowel obstruction: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Stoma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/10/2218\">",
"           Management of patients with a colostomy or ileostomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/37/24151\">",
"           Parastomal hernia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/12/28873\">",
"           Surgical principles of ostomy construction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgical site infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/23/18806\">",
"           Control measures to prevent surgical site infection following gastrointestinal procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/35/36406\">",
"           Epidemiology and pathogenesis of and risk factors for surgical site infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31290\">",
"           Overview of control measures to prevent surgical site infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Volvulus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/29/8663\">",
"           Cecal volvulus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/53/26453\">",
"           Sigmoid volvulus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-756885134B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f14_38_14944=[""].join("\n");
var outline_f14_38_14944=null;
var title_f14_38_14945="Rigid bronchoscopic instruments";
var content_f14_38_14945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rigid bronchoscopic instruments used during foreign body extraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    From top to bottom: optical forceps, rigid telescope, rigid foreign body forceps, rigid bronchoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14945=[""].join("\n");
var outline_f14_38_14945=null;
var title_f14_38_14946="Pseudolymphoma in Sjogrens";
var content_f14_38_14946=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudolymphoma in Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence staining for IgM in tissue obtained from an orbital mass in a patient with Sj&ouml;gren's syndrome. Light microscopy revealed changes compatible with a pseudolymphoma and uniform staining of the cells in the mass with IgM illustrates the monoclonal nature of the process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Creamer, MD and Marc C Hochberg, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14946=[""].join("\n");
var outline_f14_38_14946=null;
var title_f14_38_14947="Importance breast compress";
var content_f14_38_14947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Importance of breast compression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 427px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MLO view obtained with inadequate compression (Panel A), raises the question of an irregular asymmetry (arrows). On repeat imaging (Panel B) with better compression, the breast parenchyma is better visualized, with no underlying abnormality. Breast compression minimizes superimposition of tissues, and decreases patient motion, thereby improving the diagnostic quality of the study.",
"    <div class=\"footnotes\">",
"     MLO: mediolateral oblique.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14947=[""].join("\n");
var outline_f14_38_14947=null;
var title_f14_38_14948="Thoracic lymph nodes - Posterior view";
var content_f14_38_14948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Thoracic lymph nodes - Posterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 560px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the posterior view of the thoracic lymph nodes. Note the relationship of the nodes to the esophagus, trachea, heart, and great vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14948=[""].join("\n");
var outline_f14_38_14948=null;
var title_f14_38_14949="Pleur evac";
var content_f14_38_14949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pleur-evac",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Teleflex Medical Incorporated. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14949=[""].join("\n");
var outline_f14_38_14949=null;
var title_f14_38_14950="Injury record sheet";
var content_f14_38_14950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Injury record sheet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 599px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The written documentation provided by the physician&nbsp;when reporting suspected child abuse should include a sketch of the child's injuries, including skin lesions, but also including fractures, intracranial bleeding, and other injuries not visible on photographs. This form depicts six views.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Charles F. Johnson, MD, FAAP. Copyright &copy;Charles F. Johnson, MD, FAAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14950=[""].join("\n");
var outline_f14_38_14950=null;
var title_f14_38_14951="Pancreaticojej variations AGA";
var content_f14_38_14951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61669%7EGAST%2F50008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61669%7EGAST%2F50008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Variations on pancreatojejunostomies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &copy; 2003 American Gastroenterological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic decortication AGA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &copy; 2003 American Gastroenterological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14951=[""].join("\n");
var outline_f14_38_14951=null;
var title_f14_38_14952="Didanosine: Drug information";
var content_f14_38_14952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Didanosine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/13/38101?source=see_link\">",
"    see \"Didanosine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/61/30680?source=see_link\">",
"    see \"Didanosine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Videx&reg;;",
"     </li>",
"     <li>",
"      Videx&reg; EC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Videx&reg;;",
"     </li>",
"     <li>",
"      Videx&reg; EC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F159708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F159670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dosing based on patient weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pediatric powder for oral solution (Videx&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;60 kg: 125 mg twice daily (preferred) or 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;60 kg: 200 mg twice daily (preferred) or 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Delayed release capsule (Videx&reg; EC):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25 kg to &lt;60 kg: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;60 kg: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      When taken with tenofovir:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;60 kg and Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;60 kg and Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Combined use of tenofovir with didanosine is no longer recommended (DHHS, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F159689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/61/30680?source=see_link\">",
"      see \"Didanosine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Treatment of HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Pediatric powder for oral solution (Videx&reg;):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Once-daily dosing of the oral solution is not FDA approved in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 2 weeks to 8 months: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily is recommended by the manufacturer; 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     may be considered in infants 2 weeks to &lt;3 months (DHHS [pediatric], 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &gt;8 months: 120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily, not to exceed adult dose, is recommended by the manufacturer.",
"     <b>",
"      Note:",
"     </b>",
"     DHHS guidelines suggest a range of 90-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Dosing based on patient weight: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-21 years (unlabeled dose): Treatment-naive: 240 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily (maximum: 400 mg/dose) (DHHS [pediatric], 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Delayed release capsule (Videx&reg; EC):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;6 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20 kg to &lt;25 kg: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25 kg to &lt;60 kg: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;60 kg: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-21 years (unlabeled dose): Treatment-naive: 240 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily (maximum: 400 mg/dose) (DHHS [pediatric], 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F159671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Elderly patients have a higher frequency of pancreatitis (10% versus 5% in younger patients); monitor renal function and dose accordingly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F159672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: No specific guidelines available; consider dosage reduction using adjustments for adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Dosing based on patient weight, creatinine clearance, and dosage form: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Dose (mg) of Didanosine by Body Weight &minus; Adults",
"     </caption>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <col align=\"center\" width=\"90\">",
"     </col>",
"     <col align=\"center\" width=\"90\">",
"     </col>",
"     <col align=\"center\" width=\"90\">",
"     </col>",
"     <col align=\"center\" width=\"90\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Creatinine Clearance (mL/min)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;60 kg",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;60 kg",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Powder for Oral Solution",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Delayed Release Capsule",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Powder for Oral Solution",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Delayed Release Capsule",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Per manufacturer, not suitable for use in patients &lt;60 kg with Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &lt;10 mL/minute; use alternate formulation.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400 mg daily or 200 mg twice daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400 mg daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg daily or 125 mg twice daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200 mg daily or 100 mg twice daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200 mg daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150 mg daily or 75 mg twice daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10-29",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150 mg daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100 mg daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100 mg daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75 mg daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         See Note.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients requiring hemodialysis or CAPD: Dose per Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute. Didanosine is not removed via CAPD and minimal amount of dose (&le;7%) is removed by hemodialysis; no supplemental dosing necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F159673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment needed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, enteric coated beadlets, oral: 125 mg, 200 mg, 250 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Videx&reg; EC: 125 mg, 200 mg, 250 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, enteric coated pellets, oral: 200 mg, 250 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral [pediatric]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Videx&reg;: 2 g/bottle, 4 g/bottle",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Delayed release capsule",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9845084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Videx&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199211.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199211.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Videx&reg; EC:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199212.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199212.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F159641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Pediatric powder for oral solution: Administer on an empty stomach at least 30 minutes before or 2 hours after eating. Shake well prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Videx&reg; EC: Administer on an empty stomach at least 1 hour before or 2 hours after eating; swallow capsule whole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection; always to be used in combination with at least two other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F159715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Videx&reg; may be confused with Lidex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F159706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported in monotherapy studies; risk of toxicity may increase when combined with other agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (19% to 28%), amylase increased (15% to 17%), abdominal pain (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (17% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash/pruritus (7% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Uric acid increased (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Pancreatitis (1% to 7% dose dependent); patients &gt;65 years of age had a higher frequency of pancreatitis than younger patients patients (10% vs 5% in younger patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (7% to 9%), ALT increased (6% to 9%), alkaline phosphatase increased (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute renal impairment, alopecia, anaphylactoid reaction, anemia, anorexia, arthralgia, chills/fever, diabetes mellitus, dry eyes, dyspepsia, flatulence, granulocytopenia, hepatic steatosis, hepatitis, hyper-/hypoglycemia, hyperlactatemia (symptomatic), hypersensitivity,  immune reconstitution syndrome, lactic acidosis/hepatomegaly, leukopenia, lipodystrophy, liver failure, myalgia, myopathy, optic neuritis, pain, parotid gland enlargement, portal hypertension (noncirrhotic), retinal depigmentation, rhabdomyolysis, sialoadenitis, Stevens-Johnson syndrome, thrombocytopenia, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concurrent administration with allopurinol or ribavirin",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F159626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Noncirrhotic portal hypertension: Patients may develop noncirrhotic portal hypertension within months to years of starting didanosine therapy. Signs may include elevated liver enzymes, esophageal varices, hematemesis, ascites, and splenomegaly. Noncirrhotic portal hypertension may lead to liver failure and/or death. Discontinue use in patients with evidence of this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Retinal changes (including retinal depigmentation) and optic neuritis have been reported in adults and children using didanosine; patients should undergo retinal examination every 6-12 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis:",
"     <b>",
"      [U.S. Boxed Warning]: Pancreatitis (sometimes fatal) has been reported;",
"     </b>",
"     incidence is dose related. Risk factors for developing pancreatitis may include a previous history of the condition, concurrent cytomegalovirus or",
"     <i>",
"      Mycobacterium avium-intracellulare",
"     </i>",
"     infection, renal impairment, advanced age, and concomitant use of stavudine, pentamidine, or hydroxyurea; discontinue if clinical signs of pancreatitis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Occurs in ~20% of patients receiving the drug; if symptomatic, discontinue therapy; after resolution of symptoms, reinitiation of therapy at a reduced dose may be tolerated. Permanently discontinue if neuropathy recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; safety and efficacy have not been established in patients with significant hepatic disease. Patients on combination antiretroviral therapy with hepatic impairment may be at increased risk of potentially severe and fatal hepatic toxicity; consider interruption or discontinuation of therapy if hepatic impairment worsens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dose reduction recommended for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hydroxyurea and stavudine: Fatal cases of hepatotoxicity/lactic acidosis and/or severe peripheral neuropathy have been reported in HIV patients treated with didanosine with hydroxyurea and stavudine; avoid use with hydroxyurea or stavudine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tenofovir: Combined use may be associated with increased didanosine toxicity (eg, lactic acidosis, pancreatitis), immunologic nonresponse or CD4 cell decline despite viral suppression, early virologic failure and rapid resistance development; combined use is not recommended (DHHS, 2013); manufacturer labeling recommends a didanosine dose reduction  if combination is used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delayed release capsules: Didanosine delayed release capsules are indicated for once-daily use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Didanosine. Specifically, the risk of pancreatitis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Didanosine may decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May decrease the serum concentration of Didanosine. Reported with enteric coated didanosine capsules. Didanosine may decrease the serum concentration of Atazanavir. Specifically, the buffered formulation of didanosine may decrease atazanavir absorption. Management: To avoid therapeutic failure of atazanavir the drug should be administered 2 hours before or 1 hour after didanosine.  This recommendation applies to both buffered didanosine products and enteric coated didanosine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Didanosine. More specifically, this interaction is likely due to the effects of food (with which darunavir/ritonavir are taken) on didanosine, which is supposed to be given on an empty stomach. Management: Didanosine should be administered 1 hour prior to or 2 hours after administration of darunavir/ritonavir (which must be taken with food).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Febuxostat: May increase the serum concentration of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxyurea: May enhance the adverse/toxic effect of Didanosine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Didanosine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Didanosine may decrease the serum concentration of Indinavir.  Management: Indinavir should be administered on an empty stomach at least 1 hour apart from administration of buffer-containing formulations of didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of Didanosine. This interaction refers only to lopinavir/ritonavir oral solution, which must be taken with food, and is principally the result of a food-didanosine interaction. Management: Didanosine should be administered 1 hour prior to or 2 hours after administration of lopinavir/ritonavir oral solution (which must be taken with food).  Didanosine and lopinavir/ritonavir tablets can be administered together.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: May decrease the serum concentration of Didanosine. Management: If use of methadone with didanosine is necessary, enteric coated didanosine is preferred.  Avoid using didanosine powder for solution with methadone.  Increased monitoring of clinical response to didanosine (including viral load) is necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Didanosine may decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the adverse/toxic effect of Didanosine. Ribavirin may increase serum concentrations of the active metabolite(s) of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Didanosine may decrease the absorption of Rilpivirine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food. Rilpivirine may decrease the absorption of Didanosine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food.  Management: Administer didanosine on an empty stomach at least 2 hours before or 4 hours after rilpivirine, due to the requirement that rilpivirine be administered with food.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: May enhance the adverse/toxic effect of Didanosine. Lactic acidosis (possibly fatal) is of particular concern. Management: Use extreme caution and monitor for lactic acidosis with concomitant stavudine and didanosine therapy. Avoid use of stavudine and didanosine (in combination or alone) with hydroxyurea due to increased risk of serious toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine. Management: Avoid concomitant treatment with tenofovir and didanosine.  Consider altering even existing, stable treatment to avoid this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Didanosine. Management: It is recommended that didanosine be administered at least 2 hours apart from tipranavir in order to minimize any potential dosage form-related interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F159661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol increases risk of pancreatitis. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food decreases AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     ; serum levels may be decreased by 55%. Management: Administer on an empty stomach at least 30 minutes before or 2 hours after eating depending on dosage form.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F159648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Didanosine has been shown to cross the placenta. Based on data from the Antiretroviral Pregnancy Registry, an increased rate of birth defects has been observed following maternal use of didanosine during pregnancy; no pattern of defects has been observed and clinical relevance is uncertain. Pharmacokinetics are not significantly altered during pregnancy; dose adjustments are not needed. Cases of lactic acidosis/hepatic steatosis syndrome related to mitochondrial toxicity have been reported in pregnant women with prolonged use of nucleoside analogues. It is not known if pregnancy itself potentiates this known side effect; however, women may be at increased risk of lactic acidosis and liver damage. In addition, these adverse events are similar to other rare but life-threatening syndromes which occur during pregnancy (eg, HELLP syndrome). Hepatic enzymes and electrolytes should be monitored in women receiving nucleoside analogues and clinicians should watch for early signs of the syndrome. In addition, mitochondrial dysfunction may develop in infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. Due to the reports of lactic acidosis, maternal, and neonatal mortality, didanosine and stavudine should",
"     <b>",
"      not",
"     </b>",
"     be used in combination during pregnancy. The DHHS Perinatal HIV Guidelines recommend didanosine to be used only in special circumstances during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F159677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F159649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F159650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Take on an empty stomach; administer at least 30 minutes before or 2 hours after eating",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F159647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Didanosine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (30): $115.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $185.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $236.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $368.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Videx EC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (30): $162.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $259.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $330.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $515.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Videx Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (100 mL): $66.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (200 mL): $145.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F159635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, uric acid, creatinine; hemoglobin, CBC with neutrophil and platelet count, CD4 cells; viral load; liver function tests, serum bilirubin, albumin, INR, amylase; weight gain; perform dilated retinal exam every 6 months, ultrasonography (if portal hypertension suspected)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F159651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bandotan (AR);",
"     </li>",
"     <li>",
"      Bristol-Videx EC (CO);",
"     </li>",
"     <li>",
"      Cipladinex (CO);",
"     </li>",
"     <li>",
"      Didasten (MX);",
"     </li>",
"     <li>",
"      Didax (BR);",
"     </li>",
"     <li>",
"      Dinex (IN);",
"     </li>",
"     <li>",
"      Dinex EC (PE);",
"     </li>",
"     <li>",
"      Vidanovir (HN);",
"     </li>",
"     <li>",
"      Videx (AT, AU, BE, BR, CL, CN, CZ, DE, DK, EE, EG, ES, FR, GB, GR, ID, IE, IT, MT, MY, NL, PL, PT, RU, SE, SK, TR, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Videx DDI (CO);",
"     </li>",
"     <li>",
"      Videx EC (AU, BG, CH, EC, EE, FI, HK, IE, MX, MY, NO, NZ, PE, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Videx EC SR (KP);",
"     </li>",
"     <li>",
"      Videx Pediatric (HK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F159625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Didanosine, a purine nucleoside (adenosine) analog and the deamination product of dideoxyadenosine (ddA), inhibits HIV replication",
"     <i>",
"      in vitro",
"     </i>",
"     in both T cells and monocytes. Didanosine is converted within the cell to the mono-, di-, and triphosphates of ddA. These ddA triphosphates act as substrate and inhibitor of HIV reverse transcriptase substrate and inhibitor of HIV reverse transcriptase thereby blocking viral DNA synthesis and suppressing HIV replication.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F159643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Subject to degradation by acidic pH of stomach; some formulations are buffered to resist acidic pH; &le;55% reduction in peak plasma concentration is observed in presence of food. Delayed release capsules contain enteric-coated beadlets which dissolve in the small intestine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 28 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; Adults: 1.08 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Has not been evaluated in humans; studies conducted in dogs show extensive metabolism with allantoin, hypoxanthine, xanthine, and uric acid being the major metabolites found in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Children: 25%; Adults: 42%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents: 0.8 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Normal renal function: 1.5 hours; active metabolite, ddATP, has an intracellular half-life &gt;12 hours",
"     <i>",
"      in vitro",
"     </i>",
"     ; Renal impairment: 2.5-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Delayed release capsules: 2 hours; Powder for suspension: 0.25-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~55% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Total body: Averages 800 mL/minute",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Balis FM, Pizzo PA, Butler KM, et al, &ldquo;Clinical Pharmacology of 2&prime;, 3&prime;-Dideoxyinosine in Human Immunodeficiency Virus-Infected Children,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1992, 165(1):99-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/1727902/pubmed\" id=\"1727902\" target=\"_blank\">",
"        1727902",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bissuel F, Cotte L, Cruneel F, et al, &ldquo;Didanosine-Induced Fulminant Hepatitis,&rdquo; 10th Internal Conference on AID, 1994, 2:204 [abstract].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bouvet E, Casalino E, Prevost MH, et al, &ldquo;Fatal Case of 2',3'-Dideoxyinosine-Associated Pancreatitis,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1990, 336(8729):1515.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Butler KM, Husson RN, Balis FM, et al, &ldquo;Dideoxyinosine in Children With Symptomatic Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(3):137-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/1670591/pubmed\" id=\"1670591\" target=\"_blank\">",
"        1670591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chidiac C, Alfandari S, Caron J, et al, &ldquo;Diabetes Mellitus Following Treatment of AIDS With Didanosine,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1995, 9(2):215-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Faulds D and Brogden RN, &ldquo;Didanosine: A Review of Its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Potential in Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 44(1):94-116.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hilts AE and Fish DN, &ldquo;Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55:2528-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/9853641/pubmed\" id=\"9853641\" target=\"_blank\">",
"        9853641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsch MS and D'Aquila RT, &ldquo;Therapy for Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(23):1686-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/8387640/pubmed\" id=\"8387640\" target=\"_blank\">",
"        8387640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knupp CA, Hak LJ, Coakley DF, et al, &ldquo;Disposition of Didanosine in HIV-Seropositive Patients With Normal Renal Function of Chronic Renal Failure: Influence of Hemodialysis and Continuous Ambulatory Peritoneal Dialysis,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(5):535-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/8941026/pubmed\" id=\"8941026\" target=\"_blank\">",
"        8941026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kovari H, Ledergerber B, Peter U, et al, &ldquo;Association of Noncirrhotic Portal Hypertension in HIV-Infected Persons And Antiretroviral Therapy With Didanosine: A Nested Case-Control Study,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(4):626-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/19589079/pubmed\" id=\"19589079\" target=\"_blank\">",
"        19589079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lafeuillade A, Hittinger G, and Chadapaud S, &ldquo;Increased Mitochondrial Toxicity With Ribavirin in HIV/HCV Coinfection,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 357(9252):280-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/11214134/pubmed\" id=\"11214134\" target=\"_blank\">",
"        11214134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Longhurst HJ, and Pinching AJ, &ldquo;Pancreatitis Associated With Hydroxyurea in Combination with Didanosine,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 2001, 322:81.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      May DB, Drew RH, Yedinak KC, et al, &ldquo;Effect of Simultaneous Didanosine Administration on Itraconazole Absorption in Healthy Volunteers,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1994, 14(5):509-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/7997384/pubmed\" id=\"7997384\" target=\"_blank\">",
"        7997384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morse GD, Shelton MJ, and O'Donnell AM, &ldquo;Comparative Pharmacokinetics of Antiviral Nucleoside Analogues,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1993, 24(2):101-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/8453821/pubmed\" id=\"8453821\" target=\"_blank\">",
"        8453821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pelucio MT, Rothenhaus T, Smith M, et al, &ldquo;Fatal Pancreatitis as a Complication of Therapy for HIV Infection,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1995, 13(5):633-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/8530781/pubmed\" id=\"8530781\" target=\"_blank\">",
"        8530781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry CM and Balfour JA, &ldquo;Didanosine. An Update on Its Antiviral Activity, Pharmacokinetic Properties, and Therapeutic Efficacy in the Management of HIV Disease,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 52(6):928-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/8957161/pubmed\" id=\"8957161\" target=\"_blank\">",
"        8957161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathbun RC and Martin ES 3d, &ldquo;Didanosine Therapy in Patients Intolerant of or Failing Zidovudine Therapy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992, 26(11):1347-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/1362093/pubmed\" id=\"1362093\" target=\"_blank\">",
"        1362093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salmon-Ceron D, Chauvelot-Moachon L, Abad S, et al, &ldquo;Mitochondrial Toxic Effects and Ribavirin,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 357(9270):1803-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/11407389/pubmed\" id=\"11407389\" target=\"_blank\">",
"        11407389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sande MA, Carpenter CC, Cobbs CG, et al, &ldquo;Antiretroviral Therapy for Adult HIV-Infected Patients,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 270(21):2583-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/38/14952/abstract-text/7901434/pubmed\" id=\"7901434\" target=\"_blank\">",
"        7901434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9351 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-109.230.63.219-AC07DF7577-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14952=[""].join("\n");
var outline_f14_38_14952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708701\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159665\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159666\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159708\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159670\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159689\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159671\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159672\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159673\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159637\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159622\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9845084\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159641\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159640\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159715\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159706\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159644\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159626\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299187\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159631\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159661\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159633\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159648\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159677\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159649\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159650\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159647\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159635\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159651\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159625\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159643\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9351|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/13/38101?source=related_link\">",
"      Didanosine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/61/30680?source=related_link\">",
"      Didanosine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_38_14953="Ventricle parasystole tutorial";
var content_f14_38_14953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1058px;\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Ventricular parasystole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 171px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unifocal parasystolic ventricular premature beats (VPBs) occur at a rate which is slower than the underlying sinus rhythm and manifest different coupling intervals (ie, the distance between the VPB and the prior QRS complex). The ectopic focus does not always activate the ventricular myocardium (and therefore does not produe a VPB and the ECG) since it may arrive at a time when the ventricle is refractory due to activation from the normal conduction pathway. However, the interval between two successive VPBs is always some integer of the underlying rate of the ectopic focus (the interectopic intervals have a common denominator) since the ectopic focus is undisturbed and continues to fire at its own intrinsic rate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14953=[""].join("\n");
var outline_f14_38_14953=null;
var title_f14_38_14954="Paraganglioma and pheochromocytoma: Management of malignant disease";
var content_f14_38_14954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paraganglioma and pheochromocytoma: Management of malignant disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/38/14954/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/38/14954/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/38/14954/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/38/14954/contributors\">",
"     Aymen Elfiky, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/38/14954/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/38/14954/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/38/14954/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/38/14954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/38/14954/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/38/14954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H94109321\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytomas and paragangliomas are catecholamine-secreting neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla (in the case of pheochromocytomas) and from neuroendocrine cells of the extra-adrenal autonomic paraganglia (in the case of paragangliomas). While",
"    <span class=\"nowrap\">",
"     pheochromocytomas/paragangliomas",
"    </span>",
"    share overlapping characteristics that span histopathology, epidemiology, and even molecular pathobiology, they also have many differences in terms of their clinical behavior, aggressiveness and metastatic potential, biochemical findings, and association with inherited genetic syndromes.",
"   </p>",
"   <p>",
"    Although some paragangliomas, particularly those arising in the skull base and neck, do not present with symptoms of catecholamine excess, intratumoral metabolism of catecholamines to metanephrines (norepinephrine to normetanephrine, and epinephrine to metanephrine, respectively) occurs independently of catecholamine release. As a result, biochemical testing is indicated in every patient with a paraganglioma even if they do not present with a clinical picture of catecholamine hypersecretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"     \"Paragangliomas of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paragangliomas and pheochromocytomas are indistinguishable at the cellular level, and catecholamine-secreting paragangliomas often present clinically like pheochromocytomas with hypertension, episodic headache, sweating, tremor, and forceful palpitations. However, the distinction between pheochromocytoma and paraganglioma is an important one because of implications for associated neoplasms, risk for malignancy, and genetic testing.",
"   </p>",
"   <p>",
"    The study of familial pheochromocytoma syndromes has been very important in understanding the pathogenic mechanisms involved in both familial as well as sporadic forms. Several susceptibility genes have been established as playing a central role in the pathogenesis of both pheochromocytomas and paragangliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/1\">",
"     1",
"    </a>",
"    ]. At present, 10 different genes have been implicated in the pathogenesis of these tumors: the von Hippel-Lindau (",
"    <em>",
"     VHL",
"    </em>",
"    ) tumor suppressor gene, the rearranged during transfection (",
"    <em>",
"     RET",
"    </em>",
"    ) proto-oncogene, the neurofibromatosis type 1 (",
"    <em>",
"     NF1",
"    </em>",
"    ) tumor suppressor gene, genes encoding for the four subunits (A, B, C and D) of the succinate dehydrogenase (",
"    <em>",
"     SDH",
"    </em>",
"    ) complex, a gene encoding the enzyme responsible for flavination of the SDHA subunit (",
"    <em>",
"     SDHAF2",
"    </em>",
"    ), and most recently, the genes",
"    <em>",
"     TMEM127",
"    </em>",
"    and",
"    <em>",
"     MAX",
"    </em>",
"    . These were somatic mutations and not demonstrated to be linked to an inherited syndrome. Genetic studies suggest that other genes may be involved in the pathogenesis of these tumors and investigations are under way to uncover novel mutations in apparently &ldquo;sporadic&rdquo; cases. Genetic testing is recommended for all patients with a paraganglioma and in selected patients with pheochromocytoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"     \"Paragangliomas of the head and neck\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21351?source=see_link&amp;anchor=H107340331#H107340331\">",
"     \"Pheochromocytoma in genetic disorders\", section on 'Suggested approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most",
"    <span class=\"nowrap\">",
"     pheochromocytomas/paragangliomas",
"    </span>",
"    are benign. Approximately 10 percent of pheochromocytomas are malignant (as defined by the presence of metastases), while a larger proportion of paragangliomas (up to 25 percent) are malignant. Malignancy rates are highest for paragangliomas that arise in the setting of an inherited mutation in the B subunit of the succinate dehydrogenase gene (",
"    <em>",
"     SDHB",
"    </em>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"     \"Paragangliomas of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will cover treatment for advanced metastatic",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma.",
"    </span>",
"    The epidemiology, risk factors, molecular pathogenesis, histology, clinical manifestations, diagnosis, and genetic screening issues for paragangliomas and pheochromocytomas, locoregional treatment for pheochromocytomas, and locoregional treatment for paragangliomas are covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"     \"Paragangliomas of the head and neck\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link\">",
"     \"Treatment of pheochromocytoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28825788\">",
"    <span class=\"h1\">",
"     RISK OF MALIGNANCY AND IMPLICATIONS FOR PRIMARY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of malignancy in",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    is not always straightforward. Given that there is no combination of clinical, histopathologic, or biochemical features shown to reliably predict biologic behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/2\">",
"     2",
"    </a>",
"    ], pathologic evaluations generally provide little prognostic insight to predict risk of recurrence or metastases. A diagnosis of malignancy can only be made by identifying tumor deposits in tissues that do not normally contain chromaffin cells (eg, lymph nodes, liver, bone, lung, and other distant metastatic sites). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"     \"Paragangliomas of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of malignancy depends on anatomic site and genetic background:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 10 percent of pheochromocytomas are malignant compared to 20 to 25 percent of extra-adrenal abdominal and mediastinal secretory paragangliomas. In the skull base and neck, malignancy is least common for jugulotympanic tumors (2 to 4 percent), slightly higher for carotid body tumors (4 to 6 percent), and highest for vagal tumors (10 to 19 percent).",
"     </li>",
"     <li>",
"      There are large differences between the familial syndromes and their risk for malignancy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The highest malignancy rates are seen in paragangliomas associated with inherited mutations in the B subunit of the succinate dehydrogenase (",
"      <em>",
"       SDHB",
"      </em>",
"      ) gene, which are usually abdominal and secretory. These patients, who have paraganglioma syndrome type 4 (PGL4), warrant screening for distant metastatic disease as part of the preoperative evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"       \"Paragangliomas of the head and neck\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Only 3 to 5 percent of",
"      <span class=\"nowrap\">",
"       pheochromocytomas/paragangliomas",
"      </span>",
"      related to MEN2 are malignant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\", section on 'Pheochromocytoma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"       \"Paragangliomas of the head and neck\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metastases may appear more than 20 years after the original presentation, providing the rationale for long-term, posttreatment surveillance after locoregional treatment these patients.",
"   </p>",
"   <p>",
"    Among patients with malignant skull base and neck paragangliomas, metastases are most frequently found to the cervical lymph nodes. These data have led some to recommend selective lymph node dissection at the time of primary resection. Although outcomes of patients with regional nodal disease are better than those with distant metastases (five-year survival 77 versus 12 percent in the above noted series from the National Cancer Database [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/3\">",
"     3",
"    </a>",
"    ]), adjuvant radiation therapy (RT) is frequently recommended.",
"   </p>",
"   <p>",
"    In contrast, patients with paragangliomas below the skull base and neck most frequently have distant metastases, most commonly to the bone, liver, and lung. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"     \"Paragangliomas of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the presence of distant metastatic disease can have an adverse effect on prognosis, metastases do not necessarily represent a contraindication to local intervention. Interventions such as surgical debulking, ablation, or stereotactic radiotherapy represent effective options for primary management of recurrent or metastatic disease. Even if surgical intervention does not result in complete debulking, it may still be considered with palliative intent to release tumor pressure on surrounding tissues or to decrease tumor mass [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/4\">",
"     4",
"    </a>",
"    ]. A lower tumor burden can lead to a significant decrease in catecholamine secretion (for functioning tumors) as well as lowered dosage of agents used for adrenergic blockade. It can also improve the response to other therapeutic approaches. However, a survival advantage for surgical debulking has not been shown. For patients not amenable to surgery or for those that require additional postoperative therapy, a number of palliative options are available including",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG therapy, chemotherapy, radiation therapy, cryoablation therapy, radiofrequency ablation therapy, ethanol injection, tumor embolization, and peptide receptor radionuclide therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5767757\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of metastatic",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    is highly variable, with reported five-year survival rates that range widely from 12 to 84 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/3,5-14\">",
"     3,5-14",
"    </a>",
"    ]. The survival rate may depend on the primary tumor site and sites of metastases.",
"   </p>",
"   <p>",
"    Outcomes are most variable for patients with malignant paragangliomas of the skull base and neck, most of which are nonsecretory and associated with regionally limited metastases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 19 patients with malignant skull base and neck paraganglioma, the five-year survival rate was 84 percent, despite the fact that 14 had distant metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, data on 59 cases of malignant paraganglioma of the skull base and neck extracted from the National Cancer Database demonstrated a five-year survival rate of 77 percent for regionally confined metastases, but only 12 percent for patients with distant metastatic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with metastatic",
"    <span class=\"nowrap\">",
"     pheochromocytoma/secretory",
"    </span>",
"    paraganglioma, reported five-year survival rates are 34 to 60 percent, averaging approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/5-9,11-15\">",
"     5-9,11-15",
"    </a>",
"    ]. Even 10-year survival rates of 25 percent are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/15\">",
"     15",
"    </a>",
"    ]. Prognosis is impacted by tumor burden, location of metastases, and rate of progression; patients with brain, liver and lung metastases tend to have a worse prognosis than do those with isolated bone lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28826564\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT OF CATECHOLAMINE SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of catecholamine excess from functioning malignant",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paragangliomas",
"    </span>",
"    are the same as those associated with benign tumors. Among patients with malignant disease, symptoms may develop as a result of metastatic growth of the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of catecholamine excess typically include episodic hypertension, headache, palpitations, and sweating. The diagnosis is confirmed by elevated catecholamine metabolites in plasma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    raised 24-hour urinary excretion of fractionated metanephrines and catecholamines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"     \"Paragangliomas of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in patients with benign disease, symptoms of catecholamine excess can be controlled with combined alpha- and beta-adrenergic blockade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link&amp;anchor=H192460729#H192460729\">",
"     \"Treatment of pheochromocytoma in adults\", section on 'Combined alpha- and beta-adrenergic blockade'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5767604\">",
"    <span class=\"h1\">",
"     RESPONSE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response assessment in patients being treated for advanced",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    is usually performed using a combination of radiographic imaging and serial assays of fractionated metanephrines, fractionated catecholamines, and chromogranin A. &nbsp;",
"   </p>",
"   <p>",
"    One of the unique features of",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    is their slow response to therapy, particularly to radiation therapy (RT). These tumors are known to regress slowly and usually partially after RT, and successfully treated tumors demonstrate residual masses, the presence of which does not necessarily indicate treatment failure. Paragangliomas are vascular tumors, and the malignant cells constitute only a small part of the tumor mass; it is thought that the vascular elements constitute the bulk of the tumor undergoing fibrosis after treatment. Stabilization or reduction in tumor size, decreased enhancement, and reduced T2 signal intensity on magnetic resonance imaging (MRI) have all been described and are indicative of local control [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/18\">",
"     18",
"    </a>",
"    ]. Some have suggested the superiority of metabolic imaging with FDG-PET rather than anatomical cross sectional imaging with computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], but this is not a standard approach to response assessment at most institutions. &nbsp;",
"   </p>",
"   <p>",
"    Chromogranin A (CgA) is co-stored and co-released with catecholamines from chromaffin cells. Because of limited specificity, CgA is not useful for diagnostic purposes (",
"    <a class=\"graphic graphic_table graphicRef73287 \" href=\"UTD.htm?40/9/41116\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\", section on 'Chromogranin A'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, as with other neuroendocrine tumors, serum CgA levels correlate with disease burden, and serial measurement of CgA is mostly used to monitor response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/15,21-25\">",
"     15,21-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H663057\">",
"    <span class=\"h1\">",
"     THERAPEUTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial observation coupled with frequent follow-up could be considered an option for asymptomatic patients, given the indolent course in some subgroups of patients. For many patients with indolent tumors, treatment-related side effects may exceed the potential benefit of therapy. (See",
"    <a class=\"local\" href=\"#H5767757\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, for symptomatic patients or those with progressive metastatic disease, there are several therapeutic strategies for control of tumor burden. A multidisciplinary approach to management is optimal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94110027\">",
"    <span class=\"h2\">",
"     Local therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28826081\">",
"    <span class=\"h3\">",
"     Resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no curative treatments for malignant",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma.",
"    </span>",
"    However, both the primary and metastatic lesions should be resected, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/27\">",
"     27",
"    </a>",
"    ]. Resection may improve symptoms, reduce hormone secretion, prevent complications related to a critical anatomic location, and improve the efficacy of subsequent therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/16,28\">",
"     16,28",
"    </a>",
"    ]. Resection may also possibly improve survival, although there are no clinical trial data to support this [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/29\">",
"     29",
"    </a>",
"    ]. Although the five-year survival rate is less than 50 percent, many of these patients have prolonged survival and minimal morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical intervention should only be performed in centers with experience in handling patients with malignant",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma.",
"    </span>",
"    Preoperative control of the effects of excessive adrenergic stimulation, and preoperative as well as intraoperative volume expansion, are necessary. General surgical principles, including medical preparation for surgery and intraoperative hemodynamic management, are addressed elsewhere.",
"   </p>",
"   <p>",
"    Although a laparoscopic approach to resection is generally preferred for benign",
"    <span class=\"nowrap\">",
"     pheochromocytomas/paragangliomas,",
"    </span>",
"    malignant tumors are often large or located in areas that are difficult to remove laparoscopically. In cases of proven or suspected malignancy, open procedures are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/30\">",
"     30",
"    </a>",
"    ]. If a primary tumor is being resected, the capsule should not be entered surgically, if possible, as this predisposes to recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors suggest administration of 131-iodine-labeled meta-iodobenzylguanidine (",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG) after resection of a catecholamine-secreting",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    that takes up MIBG as determined by",
"    <sup>",
"     123",
"    </sup>",
"    I-MIBG scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/32\">",
"     32",
"    </a>",
"    ]. However, there are no data demonstrating a survival or relapse-free survival benefit for &ldquo;adjuvant&rdquo;",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG treatment after resection of metastatic disease. We suggest not pursuing this approach, which is in keeping with treatment guidelines for",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    from the",
"    <a class=\"external\" href=\"https://subscriptions.nccn.org/login.aspx\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    and others [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/4,16\">",
"     4,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230667\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was previously thought that malignant",
"    <span class=\"nowrap\">",
"     pheochromocytomas/paragangliomas",
"    </span>",
"    were relatively radioresistant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/33\">",
"     33",
"    </a>",
"    ]. However, external beam radiation therapy (EBRT) at doses &gt;40 Gy can provide local tumor control and relief of symptoms for tumors at a variety of sites, including the soft tissues of the skull base and neck, abdomen, and thorax, as well as painful bony metastases. In a series of 17 patients with malignant paraganglioma who received EBRT, 76 percent had local control or clinically significant symptomatic relief for at least one year or until death [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/34\">",
"     34",
"    </a>",
"    ]. Of the five patients with widespread systemic metastases and areas of bulky symptomatic tumor who received sequential",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG and EBRT, all irradiated areas showed a durable objective response; all patients eventually experienced out of field systemic progression requiring other treatment.",
"   </p>",
"   <p>",
"    The use of EBRT for primary treatment of skull base and neck paragangliomas, and the utility of stereotactic radiosurgery for primary treatment of jugulotympanic skull base and neck paragangliomas is discussed in detail elsewhere.",
"   </p>",
"   <p>",
"    Patients need to be monitored during RT, because RT-induced inflammation of the lesion can induce massive catecholamine secretion and a hypertensive crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28826108\">",
"    <span class=\"h3\">",
"     Nonsurgical ablative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several nonsurgical, local ablative therapies are available for patients with metastases, including radiofrequency ablation (RFA), cryoablation, and percutaneous ethanol injection. Percutaneous ablation for metastatic lesions at a variety of sites, including soft tissue, bone, and liver, may be safely performed if there is careful attention to periprocedural management [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/36-42\">",
"     36-42",
"    </a>",
"    ]. As with other forms of local therapy including surgery and RT, any form of local ablation can induce massive catecholamine secretion and a hypertensive crisis; preprocedure medical preparation is needed.",
"   </p>",
"   <p>",
"    The safety and efficacy of percutaneous ablation was addressed in a series of 10 patients with metastatic",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma,",
"    </span>",
"    all of whom were pretreated with alpha- and beta-adrenergic blockade as well as tyrosine hydroxylase inhibition with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/25/2452?source=see_link\">",
"     metyrosine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/36\">",
"     36",
"    </a>",
"    ]. The ablation procedure chosen (RFA, cryoablation, or ethanol injection) was based upon the lesion target location; bone, chest wall, and retroperitoneal lesions were treated with either RFA or cryoablation, while liver tumors were treated with either RFA or ethanol injection. For the lesions with follow-up imaging, successful ablation without evidence of recurrence was achieved in 15 of 27 primarily treated lesions (56 percent). Among the seven patients who had dedicated imaging performed after ablation (representing 31 treated tumors), the time to disease progression was relatively short (7.2 &plusmn; 4 months). However, amelioration of breakthrough hypertensive symptoms or metastasis-related pain was achieved in two of two and four of four patients, respectively.",
"   </p>",
"   <p>",
"    Results are best if percutaneous tumor ablation is limited to patients with one or a few relatively small (ideally, &lt;3 to 4 cm) tumors. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H438698\">",
"    <span class=\"h3\">",
"     Transarterial chemoembolization for liver metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with multiple liver metastases that are not amenable to resection or nonsurgical methods of ablation, isolated case reports suggest benefit (decreased tumor bulk and improved symptom control) from transarterial chemoembolization (TACE) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. As with other forms of local therapy, TACE can induce massive catecholamine secretion and a hypertensive crisis; preprocedure medical preparation is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28826122\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28826130\">",
"    <span class=\"h3\">",
"     Radionuclide therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic radionuclide treatment employs beta-emitting isotopes that are coupled to either metaiodobenzylguanidine (MIBG) or somatostatin analogs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28826641\">",
"    <span class=\"h4\">",
"     MIBG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic and therapeutic value of MIBG is based upon its structural similarity with noradrenaline and a high affinity to, and uptake in, chromaffin cells. Radioactive iodine (I",
"    <sup>",
"     131",
"    </sup>",
"    ) is attached to the MIBG molecule to produce",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG, which functions as a semi-selective agent for malignant",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma.",
"    </span>",
"    This treatment only works for the approximately 60 percent of tumors that take up MIBG as determined by",
"    <sup>",
"     123",
"    </sup>",
"    I-MIBG scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. A lower fraction of dopamine-secreting paragangliomas take up",
"    <sup>",
"     123",
"    </sup>",
"    I-MIBG [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. External beam RT abolishes the ability of these tumors to take up MIBG, making",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG treatment ineffective in any irradiated site [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with metastatic disease whose tumors secrete catecholamines and take up MIBG, the therapeutic value of",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG to achieve symptom palliation and tumor regression or stabilization has been shown in many small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/8,17,32,53-59\">",
"     8,17,32,53-59",
"    </a>",
"    ]. Objective response rates are approximately 30 percent, and another 40 percent of tumors remain stable; less than 5 percent have a complete remission. Hormonal response (ie, decrease in catecholamine secretion) is reported in 45 to 67 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/17,56,57\">",
"     17,56,57",
"    </a>",
"    ]. In general, better objective responses are achieved in patients with limited disease and in those with soft tissue rather than bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG treatment can be repeated, usually at six-month intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/32\">",
"     32",
"    </a>",
"    ]. The optimal dosimetry is not established. Most of the published reports have used single therapy doses between 100 to 200 mCi, with cumulative doses ranging from 557 to 2322 mCi and averaging 400 and 600 mCi [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/8,17,32,53,54,56-58\">",
"     8,17,32,53,54,56-58",
"    </a>",
"    ]. At these doses, treatment is generally well-tolerated with the main side effects being transient mild leukopenia and thrombocytopenia. Hypothyroidism was reported in 3 of 28 patients receiving cumulative doses of 111-916 mCi in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/57\">",
"     57",
"    </a>",
"    ], and in 2 of 10 patients in a second report (average cumulative dose 310 mCi) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence that higher-dose regimens (single doses 500 to 800 mCi) can result in sustained complete response in a small number of patients, albeit with a higher risk of potentially serious side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/55,60\">",
"     55,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 12 patients with malignant pheochromocytoma received a single",
"      <sup>",
"       131",
"      </sup>",
"      I-MIBG treatment with 12 to 18",
"      <span class=\"nowrap\">",
"       mCi/kg;",
"      </span>",
"      repeat treatments (median interval between treatments 4.4 months, range 3 to 7 months) were administered on a case-by-case basis to improve the overall response [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/55\">",
"       55",
"      </a>",
"      ]. At a median follow-up of 45 months, two died without a response, three remained in a complete remission (two of whom had both soft tissue and skeletal metastases), and seven had a documented partial remission. However, 79 percent had grade 3 thrombocytopenia, 72 percent had grade 3 or 4 neutropenia, and one patient required autologous stem cell rescue for hematologic recovery. All patients received treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      to prevent",
"      <sup>",
"       131",
"      </sup>",
"      I uptake by the thyroid, and there were no cases of hypothyroidism.",
"     </li>",
"     <li>",
"      In a subsequent phase II study, 50 patients with metastatic",
"      <span class=\"nowrap\">",
"       pheochromocytoma/paraganglioma",
"      </span>",
"      received single",
"      <sup>",
"       131",
"      </sup>",
"      I-MIBG doses ranging from 492 to 1160 mCi (6 to 19",
"      <span class=\"nowrap\">",
"       mCi/kg,",
"      </span>",
"      median 12",
"      <span class=\"nowrap\">",
"       mCi/kg);",
"      </span>",
"      cumulative doses ranged from 492 to 3191 mCi [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/60\">",
"       60",
"      </a>",
"      ]. Patients had to have successful peripheral blood stem cell harvest to receive &gt;12",
"      <span class=\"nowrap\">",
"       mCi/kg.",
"      </span>",
"      Overall, a complete response was achieved in 10 percent, a partial response in 20 percent, and 39 percent had stable",
"      <span class=\"nowrap\">",
"       disease/minor",
"      </span>",
"      response (69 percent disease control rate). The five-year overall survival rate was 64 percent.",
"      <br/>",
"      <br/>",
"      Toxicities included grade 3 to 4 neutropenia in 87 percent and grade 3 or 4 thrombocytopenia in 87 percent; four patients experienced prolonged myelosuppression that required autologous hematopoietic cell rescue. Other serious toxicity included grade 4 acute respiratory distress syndrome and cryptogenic organizing pneumonia in two patients each, and myelodysplastic syndrome and concurrent acute leukemia in two patients who received multiple infusions of",
"      <sup>",
"       131",
"      </sup>",
"      I-MIBG. Hypothyroidism was not reported, although large doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      were administered to prevent uptake of",
"      <sup>",
"       131",
"      </sup>",
"      I by the thyroid, and three became hyperthyroid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG should be considered in patients with good uptake of",
"    <sup>",
"     123",
"    </sup>",
"    I-MIBG by dosimetry who fall into one of the following categories: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unresectable progressive",
"      <span class=\"nowrap\">",
"       pheochromocytoma/paraganglioma",
"      </span>",
"     </li>",
"     <li>",
"      Symptoms from disease that is not amenable to locoregional methods of control",
"     </li>",
"     <li>",
"      A high tumor burden and a low number of bone metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with rapidly progressive tumors or bone-predominant extensive disease, chemotherapy is a preferred option even if",
"    <sup>",
"     123",
"    </sup>",
"    I-MIBG scintigraphy is positive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the fact that most studies use different doses of",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG and schedules, and include only a few patients, specific recommendations as to the best dose and treatment schedule cannot be made [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/4\">",
"     4",
"    </a>",
"    ]. Multicenter studies are required to reach a consensus on the efficacy of high-dose versus fractionated medium doses of",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/16\">",
"     16",
"    </a>",
"    ]. Some institutions with extensive experience with this compound use high-dose",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG for selected patients with aggressive disease who are able to tolerate it. Thyroidal uptake of free iodide is prevented by giving an oral saturated solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    at 24 hours prior to planned administration and daily for 10 days post therapy. At other institutions, medium-dose",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG is used for patients with relatively indolent disease, with chemotherapy preferred over high-dose",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG for those with more aggressive disease. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28826656\">",
"    <span class=\"h4\">",
"     Radiolabeled somatostatin analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytomas and extra-adrenal paragangliomas express somatostatin receptors at a level that is similar to that of other neuroendocrine tumors, including gastroenteropancreatic neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. As with other neuroendocrine tumors, patients whose metastatic or recurrent",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    expresses somatostatin receptors (as determined by positive uptake with",
"    <sup>",
"     111",
"    </sup>",
"    In-pentetreotide or where available, positron emission tomography [PET] imaging using gallium-68-labeled somatostatin analogs such as",
"    <sup>",
"     68",
"    </sup>",
"    Ga-DOTA-TOC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]) may benefit from therapy using radiolabeled somatostatin analogs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949126#H190949126\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Radiolabeled somatostatin analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term potential side effects of therapy with radiolabeled somatostatin analogs may include loss of renal function, pancytopenia, and myelodysplastic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly used radionuclides are Yttrium-90-labeled DOTA",
"    <sup>",
"     0",
"    </sup>",
"    -Tyr",
"    <sup>",
"     3",
"    </sup>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (",
"    <sup>",
"     90",
"    </sup>",
"    Y-edotreotide,",
"    <sup>",
"     90",
"    </sup>",
"    Y-DOTA-TOC) and lutetium-177-DOTA",
"    <sup>",
"     0",
"    </sup>",
"    -Tyr",
"    <sup>",
"     3",
"    </sup>",
"    -octreotate (",
"    <sup>",
"     177",
"    </sup>",
"    Lu-DOTATATE). The efficacy of",
"    <sup>",
"     90",
"    </sup>",
"    Y-DOTA-TOC and",
"    <sup>",
"     177",
"    </sup>",
"    Lu-DOTATATE for malignant",
"    <span class=\"nowrap\">",
"     paraganglioma/pheochromocytoma",
"    </span>",
"    has been described in isolated case reports and small series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. In the largest report, 28 patients with progressive, surgically incurable",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    received",
"    <sup>",
"     90",
"    </sup>",
"    Y-DOTA-TOC alone or sequentially with",
"    <sup>",
"     177",
"    </sup>",
"    Lu-DOTATATE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/72\">",
"     72",
"    </a>",
"    ]. The best response was two partial remissions, five minor responses, and 13 cases of stable disease (disease control rate 71 percent). At a mean followup of 19 months, 10 of the 20 patients with an objective response or stable disease still had not progressed, and there were only two cases of mild hematologic toxicity and no renal insufficiency.",
"   </p>",
"   <p>",
"    At least in the United States, the use of radiolabeled somatostatin analogs for the treatment of advanced neuroendocrine tumors, including malignant",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma,",
"    </span>",
"    remains investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28826478\">",
"    <span class=\"h3\">",
"     Octreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic effect of treating metastatic",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    with the somatostatin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    has been analyzed in a few studies with small patient numbers, and the results are mixed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Case reports suggest benefit for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      in producing objective responses in a small number of patients with advanced malignant paraganglioma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/73,74\">",
"       73,74",
"      </a>",
"      ] and for short-term reduction of catecholamine secretion in a patient with pheochromocytoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, others have failed to show benefit for short-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      administration either for control of catecholamine secretion or for preoperative reduction in tumor size [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/76-79\">",
"       76-79",
"      </a>",
"      ]. None of these studies reported rates of tumor stability; at least in the setting of metastatic gastroenteropancreatic neuroendocrine tumors, the main benefit of somatostatin analogs is in disease stabilization rather than objective tumor regression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948928#H190948928\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Octreotide and other somatostatin analogs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon this limited amount of data, the utility of somatostatin analog therapy for tumor control or palliation of symptoms in patients with malignant",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    remains unclear. However, a therapeutic trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    could be considered in a patient who is not yet a candidate for more toxic systemic treatment options. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28826173\">",
"    <span class=\"h3\">",
"     Cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy should be considered for patients with unresectable and rapidly progressive",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    and patients with high tumor burden or a large number of bone metastases.",
"   </p>",
"   <p>",
"    Most literature reports evaluating cytotoxic chemotherapy for progressive metastatic paraganglioma predominantly involve patients with retroperitoneal sympathetic catecholamine-secreting tumors. The most extensive data are from studies using various combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/9,80-82\">",
"     9,80-82",
"    </a>",
"    ]. The following illustrates the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early trial of CVD (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [750",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      [1.4",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1], and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      [600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 2] of each 21- to 28-day cycle) reported high response rates and symptomatic improvement with this regimen in 14 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/83\">",
"       83",
"      </a>",
"      ]. Details of the regimen and long-term outcomes (median follow-up 22 years) in this cohort, as well as four others who met the original eligibility criteria for the trial, were described in a later report [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/81\">",
"       81",
"      </a>",
"      ]. Overall, 10 of 18 patients (56 percent) had a complete or partial objective response to therapy, and three others had a \"minor response\" [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/81\">",
"       81",
"      </a>",
"      ]. Biochemical responses were seen in 13 (72 percent). Patients whose tumors were scored as complete or partial response received a mean of 27.4 cycles of CVD (median of 23 cycles). The median duration of response was 20 months (range 7 to 126 months), and the median survival for all patients was 3.3 years from the start of chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/81\">",
"       81",
"      </a>",
"      ]. Treatment was well tolerated, with the most prominent side effects being \"mild\" myelosuppression, peripheral neuropathy, and gastrointestinal toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The largest single-institution retrospective series of chemotherapy included 52 patients with progressive metastatic pheochromocytoma or sympathetic extra-adrenal paraganglioma who received a variety of chemotherapy regimens, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      (CyVADIC, n = 19); cyclophosphamide, doxorubicin, and dacarbazine (CyADIC, n = 12); cyclophosphamide, vincristine, and dacarbazine (CyVDic, n = 10); or a variety of other regimens (n = 11) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/9\">",
"       9",
"      </a>",
"      ]. Of the 52 evaluable patients, 17 (33 percent) responded to frontline chemotherapy, including 13 with an objective tumor response (25 percent), and four with normalization of blood pressure. In two patients with initially unresectable tumors, the response to chemotherapy was sufficient to permit subsequent surgical excision. Responders, all of whom received a chemotherapy regimen that contained dacarbazine and cyclophosphamide, survived longer than nonresponders (median 6.4 versus 3.7 years). However, nonresponders also had significantly larger tumors (10 versus 5 cm) and a higher percentage of extra-adrenal primaries, two factors that are associated with decreased overall survival in",
"      <span class=\"nowrap\">",
"       pheochromocytoma/paraganglioma",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/14\">",
"       14",
"      </a>",
"      ]. The overall survival rate of the entire cohort at five years was 51 percent.",
"     </li>",
"     <li>",
"      Single case reports and small series suggest that these tumors may also respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      alone [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/84\">",
"       84",
"      </a>",
"      ], temozolomide plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/85\">",
"       85",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/86\">",
"       86",
"      </a>",
"      ], single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/87\">",
"       87",
"      </a>",
"      ], gemcitabine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/88\">",
"       88",
"      </a>",
"      ]&nbsp;or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/89\">",
"       89",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"       streptozocin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/90\">",
"       90",
"      </a>",
"      ], or paclitaxel alone [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28826180\">",
"    <span class=\"h3\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    is a potent inhibitor of multiple tyrosine kinase receptors, including vascular endothelial growth factor receptors 1 and 2, platelet-derived growth factor receptors beta, KIT, FLT3, and RET. Early reports suggest utility for sunitinib in patients with malignant",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/92-96\">",
"     92-96",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of three patients with metastatic paraganglioma treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      (50 mg daily four weeks on, two weeks off), one patient achieved a near complete response, and two others had partial responses; two patients continued to benefit from the drug beyond 40 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The largest retrospective series included 17 patients with progressive metastatic",
"      <span class=\"nowrap\">",
"       pheochromocytoma/sympathetic",
"      </span>",
"      paraganglioma who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      monotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/38/14954/abstract/96\">",
"       96",
"      </a>",
"      ]. Four patients had metastatic disease that was limited to the skeleton, and response assessment in this group consisted of",
"      <span class=\"nowrap\">",
"       FDG-PET/CT",
"      </span>",
"      only. Of 14 evaluable patients, three had a partial response (21 percent) and five had stable disease (36 percent). Median progression-free survival was 4.1 months. Of the 14 patients with hypertension secondary to excessive catecholamine secretion, six eventually improved and this correlated with a reduction in the dose",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      number of antihypertensive medications; however, blood pressure initially worsened in the three months after starting sunitinib in five. Besides hypertension, the most common side effects were diarrhea, hand-foot syndrome, sore mouth, and fatigue. The median overall survival of the entire group was 27 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further information on the benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    should be forthcoming from a European randomized, phase II placebo-controlled trial testing sunitinib in patients with malignant",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT01371201\">",
"     FIRST-MAPPP trial",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although hypertension is one of the most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , the drug can be safely used in patients with pheochromocytoma and secretory paragangliomas as long as strict follow-up and aggressive antihypertensive dosage adjustments are performed. Sunitinib should be initiated only after normal or near normal blood pressure is achieved with combined alpha and beta adrenergic blockade. After treatment initiation, additional antihypertensive drugs or dose increase are usually required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94110493\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pheochromocytomas and paragangliomas are catecholamine-secreting neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla (in the case of pheochromocytomas) and the extra-adrenal autonomic paraganglia (in the case of paragangliomas). Paragangliomas can arise in the skull base and neck (where the majority are nonsecretory), or below the neck in the thorax or abdomen (where the majority are secretory). (See",
"      <a class=\"local\" href=\"#H94109321\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most",
"      <span class=\"nowrap\">",
"       pheochromocytomas/paragangliomas",
"      </span>",
"      are benign. Approximately 10 percent of pheochromocytomas are malignant (as defined by the presence of metastases) compared to 20 to 25 percent of extra-adrenal abdominal and mediastinal secretory paragangliomas. In the skull base and neck, malignancy is least common for jugulotympanic tumors (2 to 4 percent), slightly higher for carotid body tumors (4 to 6 percent), and highest for vagal tumors (10 to 19 percent).",
"      <br/>",
"      <br/>",
"      Among patients with malignant skull base and neck paragangliomas, metastases are most frequently limited to the regional lymph nodes. In contrast, patients with paragangliomas below the skull base and neck most frequently have distant metastases, most commonly to the bone, liver, and lung. While the presence of distant metastatic disease has an adverse effect on prognosis, metastases do not necessarily represent a contraindication to resection of the primary tumor, particularly if the metastases are surgically resectable. (See",
"      <a class=\"local\" href=\"#H28825788\">",
"       'Risk of malignancy and implications for primary therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis of metastatic",
"      <span class=\"nowrap\">",
"       pheochromocytoma/paraganglioma",
"      </span>",
"      is variable. Long-term survival is possible even in the presence of distant metastatic disease, but five-year survival rates are &le;50 percent. (See",
"      <a class=\"local\" href=\"#H5767757\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231634\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A proposed treatment algorithm for malignant",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef87044 \" href=\"UTD.htm?24/18/24879\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of catecholamine excess should be controlled using combined alpha- and beta-adrenergic blockade. (See",
"      <a class=\"local\" href=\"#H28826564\">",
"       'Medical management of catecholamine secretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest resection of both the primary and metastatic lesions, if possible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Even if complete eradication is not achievable, a cytoreductive incomplete resection can improve symptoms, reduce hormone secretion, prevent complications related to tumor in a critical anatomic location, and improve the response to subsequent therapies. However, there is no evidence that surgical debulking prolongs survival in patients with metastatic disease. (See",
"      <a class=\"local\" href=\"#H28826081\">",
"       'Resection'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Preoperative control of the effects of excessive adrenergic stimulation is necessary using combined alpha and beta blockade. In addition, preoperative and intraoperative treatment with volume expansion is required to prevent intraoperative hypotension.",
"     </li>",
"     <li>",
"      Several other forms of local therapy are available if resection is not feasible:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who are not candidates for resection, local control of bulky symptomatic disease, particularly painful bone metastases, can be achieved with external beam radiation therapy (RT). (See",
"      <a class=\"local\" href=\"#H1230667\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Percutaneous ablation of metastatic lesions at a variety of sites, including soft tissue, bone, and liver, may be safely performed using radiofrequency ablation, cryoablation therapy, or ethanol injection if there is careful attention to periprocedural management. (See",
"      <a class=\"local\" href=\"#H28826108\">",
"       'Nonsurgical ablative therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another option for local control of liver metastases in patients with multiple liver-isolated metastases that are not amenable to resection or nonsurgical methods of ablation is transarterial chemoembolization (transcatheter arterial chemoembolization). (See",
"      <a class=\"local\" href=\"#H438698\">",
"       'Transarterial chemoembolization for liver metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any form of local therapy can induce massive catecholamine secretion and a hypertensive crisis; preprocedure medical preparation is needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 60 percent of",
"      <span class=\"nowrap\">",
"       pheochromocytomas/paragangliomas",
"      </span>",
"      take up metaiodobenzylguanidine (MIBG) as determined by",
"      <sup>",
"       123",
"      </sup>",
"      I-MIBG scintigraphy. For patients with MIBG-positive tumors who have unresectable, symptomatic progressive disease that is not amenable to locoregional methods of control, or those with a high tumor burden who have a low number of bone metastases, we suggest",
"      <sup>",
"       131",
"      </sup>",
"      I-MIBG rather than systemic chemotherapy as a first-line approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There is no consensus as to the relative efficacy of high-dose versus fractionated medium doses of",
"      <sup>",
"       131",
"      </sup>",
"      I-MIBG, and specific recommendations as to the best dose and treatment schedule cannot be made. (See",
"      <a class=\"local\" href=\"#H28826641\">",
"       'MIBG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with rapidly progressive tumors or disease that is predominantly localized to the skeleton, chemotherapy is preferred even if",
"      <sup>",
"       123",
"      </sup>",
"      I-MIBG scintigraphy is positive. Although the optimal regimen is not established, we suggest combination chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28826173\">",
"       'Cytotoxic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preliminary reports suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      may be an active agent, and further ongoing studies should provide more information on its utility; hypertension is a prominent side effect. Sunitinib can be safely used, even for patients with symptoms of catecholamine excess, as long as strict follow-up and aggressive antihypertensive dosage adjustments are performed. (See",
"      <a class=\"local\" href=\"#H28826180\">",
"       'Molecularly targeted therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/1\">",
"      Kantorovich V, Pacak K. Pheochromocytoma and paraganglioma. Prog Brain Res 2010; 182:343.",
"     </a>",
"    </li>",
"    <li>",
"     Pathology and Genetics of Tumours of the Endocrine Organs. WHO Classification of Tumours, DeLellis RA, Lloyd RV, Heitz PU, Eng C.  (Eds), IARC press, Lyon, France 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/3\">",
"      Lee JH, Barich F, Karnell LH, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer 2002; 94:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/4\">",
"      Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/5\">",
"      Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004; 11:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/6\">",
"      Young AL, Baysal BE, Deb A, Young WF Jr. Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J Clin Endocrinol Metab 2002; 87:4101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/7\">",
"      Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999; 229:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/8\">",
"      Fitzgerald PA, Goldsby RE, Huberty JP, et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 2006; 1073:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/9\">",
"      Ayala-Ramirez M, Feng L, Habra MA, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 2012; 118:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/10\">",
"      Moskovic DJ, Smolarz JR, Stanley D, et al. Malignant head and neck paragangliomas: is there an optimal treatment strategy? Head Neck Oncol 2010; 2:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/11\">",
"      Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007; 92:3822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/12\">",
"      Sisson JC, Shulkin BL, Esfandiari NH. Courses of malignant pheochromocytoma: implications for therapy. Ann N Y Acad Sci 2006; 1073:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/13\">",
"      Nomura K, Kimura H, Shimizu S, et al. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 2009; 94:2850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/14\">",
"      Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011; 96:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/15\">",
"      Szalat A, Fraenkel M, Doviner V, et al. Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine 2011; 39:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/16\">",
"      Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007; 3:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/17\">",
"      Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997; 20:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/18\">",
"      Mukherji SK, Kasper ME, Tart RP, Mancuso AA. Irradiated paragangliomas of the head and neck: CT and MR appearance. AJNR Am J Neuroradiol 1994; 15:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/19\">",
"      Argiris A, Mellott A, Spies S. PET scan assessment of chemotherapy response in metastatic paraganglioma. Am J Clin Oncol 2003; 26:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/20\">",
"      Nakazawa A, Higuchi T, Oriuchi N, et al. Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma. Eur J Nucl Med Mol Imaging 2011; 38:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/21\">",
"      Grossrubatscher E, Dalino P, Vignati F, et al. The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf) 2006; 65:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/22\">",
"      B&iacute;lek R, Safar&iacute;k L, Ciprov&aacute; V, et al. Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res 2008; 57 Suppl 1:S171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/23\">",
"      Cleary S, Phillips JK, Huynh TT, et al. Chromogranin a expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Horm Metab Res 2007; 39:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/24\">",
"      d'Herbomez M, Gouze V, Huglo D, et al. Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma. J Nucl Med 2001; 42:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/25\">",
"      Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/26\">",
"      Andersen KF, Altaf R, Krarup-Hansen A, et al. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach. Cancer Treat Rev 2011; 37:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/27\">",
"      Noda T, Nagano H, Miyamoto A, et al. Successful outcome after resection of liver metastasis arising from an extraadrenal retroperitoneal paraganglioma that appeared 9 years after surgical excision of the primary lesion. Int J Clin Oncol 2009; 14:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/28\">",
"      Joseph L. Malignant phaeochromocytoma of the organ of Zuckerkandl with functioning metastases. Br J Urol 1967; 39:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/29\">",
"      Huang KH, Chung SD, Chen SC, et al. Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institute. Int J Urol 2007; 14:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/30\">",
"      Adjall&eacute; R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009; 41:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/31\">",
"      Li ML, Fitzgerald PA, Price DC, Norton JA. Iatrogenic pheochromocytomatosis: a previously unreported result of laparoscopic adrenalectomy. Surgery 2001; 130:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/32\">",
"      Mukherjee JJ, Kaltsas GA, Islam N, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 2001; 55:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/33\">",
"      Drasin H. Treatment of malignant pheochromocytoma. West J Med 1978; 128:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/34\">",
"      Fishbein L, Bonner L, Torigian DA, et al. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG. Horm Metab Res 2012; 44:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/35\">",
"      Teno S, Tanabe A, Nomura K, Demura H. Acutely exacerbated hypertension and increased inflammatory signs due to radiation treatment for metastatic pheochromocytoma. Endocr J 1996; 43:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/36\">",
"      McBride JF, Atwell TD, Charboneau WJ, et al. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol 2011; 22:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/37\">",
"      Mamlouk MD, vanSonnenberg E, Stringfellow G, et al. Radiofrequency ablation and biopsy of metastatic pheochromocytoma: emphasizing safety issues and dangers. J Vasc Interv Radiol 2009; 20:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/38\">",
"      Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003; 97:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/39\">",
"      Maithel SK, Fong Y. Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol 2009; 100:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/40\">",
"      Pacak K, Fojo T, Goldstein DS, et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst 2001; 93:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/41\">",
"      Venkatesan AM, Locklin J, Lai EW, et al. Radiofrequency ablation of metastatic pheochromocytoma. J Vasc Interv Radiol 2009; 20:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/42\">",
"      Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 1995; 76:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/43\">",
"      Hidaka S, Hiraoka A, Ochi H, et al. Malignant pheochromocytoma with liver metastasis treated by transcatheter arterial chemo-embolization (TACE). Intern Med 2010; 49:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/44\">",
"      Watanabe D, Tanabe A, Naruse M, et al. Transcatheter arterial embolization for the treatment of liver metastases in a patient with malignant pheochromocytoma. Endocr J 2006; 53:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/45\">",
"      Takahashi K, Ashizawa N, Minami T, et al. Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Intern Med 1999; 38:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/46\">",
"      Homma K, Hayashi K, Wakino S, et al. Primary malignant hepatic pheochromocytoma with negative adrenal scintigraphy. Hypertens Res 2006; 29:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/47\">",
"      Tanaka S, Ito T, Tomoda J, et al. Malignant pheochromocytoma with hepatic metastasis diagnosed 20 years after resection of the primary adrenal lesion. Intern Med 1993; 32:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/48\">",
"      van der Harst E, de Herder WW, Bruining HA, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001; 86:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/49\">",
"      Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 2005; 257:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/50\">",
"      Foo SH, Chan SP, Ananda V, Rajasingam V. Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management. Singapore Med J 2010; 51:e89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/51\">",
"      Proye C, Fossati P, Fontaine P, et al. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 1986; 100:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/52\">",
"      Van Der Horst-Schrivers AN, Osinga TE, Kema IP, et al. Dopamine excess in patients with head and neck paragangliomas. Anticancer Res 2010; 30:5153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/53\">",
"      Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 1992; 15:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/54\">",
"      Safford SD, Coleman RE, Gockerman JP, et al. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003; 134:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/55\">",
"      Rose B, Matthay KK, Price D, et al. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003; 98:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/56\">",
"      Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008; 35:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/57\">",
"      Shapiro B, Sisson JC, Wieland DM, et al. Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991; 35:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/58\">",
"      Rachh SH, Abhyankar S, Basu S. [&sup1;&sup3;&sup1;I]Metaiodobenzylguanidine therapy in neural crest tumors: varying outcome in different histopathologies. Nucl Med Commun 2011; 32:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/59\">",
"      Shilkrut M, Bar-Deroma R, Bar-Sela G, et al. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience. Am J Clin Oncol 2010; 33:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/60\">",
"      Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009; 27:4162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/61\">",
"      Hubalewska-Dydejczyk A, Trofimiuk M, Sowa-Staszczak A, et al. [Somatostatin receptors expression (SSTR1-SSTR5) in pheochromocytomas]. Przegl Lek 2008; 65:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/62\">",
"      Saveanu A, Muresan M, De Micco C, et al. Expression of somatostatin receptors, dopamine D��� receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011; 18:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/63\">",
"      de Herder WW, Hofland LJ. Somatostatin receptors in pheochromocytoma. Front Horm Res 2004; 31:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/64\">",
"      Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003; 88:5150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/65\">",
"      Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/66\">",
"      Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/67\">",
"      Mamede M, Carrasquillo JA, Chen CC, et al. Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 2006; 27:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/68\">",
"      Gulenchyn KY, Yao X, Asa SL, et al. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol) 2012; 24:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/69\">",
"      Cecchin D, Schiavi F, Fanti S, et al. Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas. J Clin Oncol 2011; 29:e171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/70\">",
"      van Essen M, Krenning EP, Kooij PP, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006; 47:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/71\">",
"      Garkavij M, Nickel M, Sj&ouml;green-Gleisner K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer 2010; 116:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/72\">",
"      Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 2008; 52:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/73\">",
"      Tenenbaum F, Schlumberger M, Lumbroso J, Parmentier C. Beneficial effects of octreotide in a patient with a metastatic paraganglioma. Eur J Cancer 1996; 32A:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/74\">",
"      Kau R, Arnold W. Somatostatin receptor scintigraphy and therapy of neuroendocrine (APUD) tumors of the head and neck. Acta Otolaryngol 1996; 116:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/75\">",
"      Koriyama N, Kakei M, Yaekura K, et al. Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: a case report with in vitro studies. Horm Res 2000; 53:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/76\">",
"      Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, et al. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clin Endocrinol (Oxf) 2002; 57:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/77\">",
"      Invitti C, De Martin I, Bolla GB, et al. Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors. Horm Res 1993; 40:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/78\">",
"      Plouin PF, Bertherat J, Chatellier G, et al. Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial. Clin Endocrinol (Oxf) 1995; 42:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/79\">",
"      Duet M, Guichard JP, Rizzo N, et al. Are somatostatin analogs therapeutic alternatives in the management of head and neck paragangliomas? Laryngoscope 2005; 115:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/80\">",
"      Patel SR, Winchester DJ, Benjamin RS. A 15-year experience with chemotherapy of patients with paraganglioma. Cancer 1995; 76:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/81\">",
"      Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008; 113:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/82\">",
"      Edstr&ouml;m Elder E, Hjelm Skog AL, H&ouml;&ouml;g A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 2003; 29:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/83\">",
"      Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/84\">",
"      Bravo EL, Kalmadi SR, Gill I. Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. Horm Metab Res 2009; 41:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/85\">",
"      Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/86\">",
"      Nozi&egrave;res C, Walter T, Joly MO, et al. A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine. Eur J Endocrinol 2012; 166:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/87\">",
"      Mora J, Cruz O, Parareda A, et al. Treatment of disseminated paraganglioma with gemcitabine and docetaxel. Pediatr Blood Cancer 2009; 53:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/88\">",
"      Pipas JM, Krywicki RF. Treatment of progressive metastatic glomus jugulare tumor (paraganglioma) with gemcitabine. Neuro Oncol 2000; 2:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/89\">",
"      Kamoshima Y, Sawamura Y, Hokari M, et al. Craniocervical paraganglioma with numerous pulmonary metastases--case report. Neurol Med Chir (Tokyo) 2008; 48:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/90\">",
"      Chow SN, Seear M, Anderson R, Magee F. Multiple pulmonary chemodectomas in a child: results of four different therapeutic regimens. J Pediatr Hematol Oncol 1998; 20:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/91\">",
"      Kruijtzer CM, Beijnen JH, Swart M, Schellens JH. Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature. Cancer Chemother Pharmacol 2000; 45:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/92\">",
"      Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009; 94:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/93\">",
"      Jimenez C, Cabanillas ME, Santarpia L, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 2009; 94:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/94\">",
"      Hahn NM, Reckova M, Cheng L, et al. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 2009; 27:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/95\">",
"      Park KS, Lee JL, Ahn H, et al. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol 2009; 39:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/38/14954/abstract/96\">",
"      Ayala-Ramirez M, Chougnet CN, Habra MA, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 2012; 97:4040.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86953 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14954=[""].join("\n");
var outline_f14_38_14954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H94110493\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94109321\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28825788\">",
"      RISK OF MALIGNANCY AND IMPLICATIONS FOR PRIMARY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5767757\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28826564\">",
"      MEDICAL MANAGEMENT OF CATECHOLAMINE SECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5767604\">",
"      RESPONSE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H663057\">",
"      THERAPEUTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94110027\">",
"      Local therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28826081\">",
"      - Resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1230667\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28826108\">",
"      - Nonsurgical ablative therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H438698\">",
"      - Transarterial chemoembolization for liver metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28826122\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28826130\">",
"      - Radionuclide therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28826641\">",
"      MIBG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28826656\">",
"      Radiolabeled somatostatin analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28826478\">",
"      - Octreotide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28826173\">",
"      - Cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28826180\">",
"      - Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94110493\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231634\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/86953\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/86953|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/18/24879\" title=\"algorithm 1\">",
"      Treatment algorithm malignant pheochromocytoma and paraganglioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/86953|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/9/41116\" title=\"table 1\">",
"      Conditions associated with elevated chromogranin A",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=related_link\">",
"      Paragangliomas of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21351?source=related_link\">",
"      Pheochromocytoma in genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_38_14955="Allergen avoidance restaurants";
var content_f14_38_14955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F76289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F76289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential allergen avoidance pitfalls in restaurant meals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Shared food preparation (blender, pan, fryer, grill, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cross contact of primary food with allergen (eg, vanilla ice cream previously contacted with peanut ice cream from prior scoop, vegetable tray containing walnut from a prior spill)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor communication between consumer and chef",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hidden or \"secret ingredients\" (allergen in sauces, powder forms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cross contact during serving (buffet, preparation trays, garnish, spills)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Addition of allergen after final preparation (added butter, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Removal of ingredient with residual allergen (removing nuts from a salad)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foods prepared in advance and ingredients unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergen used without notion of \"ingredient\" (peanut butter to seal an egg roll, nuts for decoration)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14955=[""].join("\n");
var outline_f14_38_14955=null;
var title_f14_38_14956="Vaccine schedule age 7 to 18 years PI";
var content_f14_38_14956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended vaccine schedule for children age 7 to 18 years (United States, 2013)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Notes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 to 18 years",
"       </td>",
"       <td>",
"        Influenza (flu)",
"       </td>",
"       <td>",
"        1 dose each year",
"       </td>",
"       <td>",
"        Children get 1 dose each fall. Children younger than 9 years who are getting the flu vaccine for the first time need 2 doses, given at least 1 month apart.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        11 to 12 years",
"       </td>",
"       <td>",
"        Tetanus, diphtheria, pertussis (Tdap booster)",
"       </td>",
"       <td>",
"        1 of 1",
"       </td>",
"       <td>",
"        This is usually given at age 11 to 12 years, but can be given later, at any age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human papillomavirus (HPV)",
"       </td>",
"       <td>",
"        3 doses",
"       </td>",
"       <td>",
"        This is usually given at age 11 to 12 years, but can be given from age 9 to 26. People get 3 doses over 6 months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11 to 18 years",
"       </td>",
"       <td>",
"        Meningococcal",
"       </td>",
"       <td>",
"        2 doses",
"       </td>",
"       <td>",
"        The first dose is usually given at age 11 to 12 years. A booster dose is usually given at age 16.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        The following vaccines might be given to children with certain conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7 to 10 years",
"       </td>",
"       <td>",
"        Meningococcal",
"       </td>",
"       <td>",
"        1 dose",
"       </td>",
"       <td>",
"        This is given to children earlier than the recommended age if they have certain medical conditions, or live in or travel to certain places.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        7 to 18 years",
"       </td>",
"       <td>",
"        Pneumococcal",
"       </td>",
"       <td>",
"        1 or 2 doses",
"       </td>",
"       <td>",
"        This is given to children who have certain medical conditions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis A (HepA)",
"       </td>",
"       <td>",
"        2 doses",
"       </td>",
"       <td>",
"        Some children who never got this vaccine might need it.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: If your child didn't get all of his or her scheduled vaccines from age 0 to 6 years, he or she might need to get those vaccines from age 7 to 18.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14956=[""].join("\n");
var outline_f14_38_14956=null;
var title_f14_38_14957="Rate TE ICH CHADS2 warfarin";
var content_f14_38_14957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adjusted rates and rate differences for thromboembolism and ICH, by warfarin status*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"3\">",
"       Risk factor",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"5\">",
"       Thromboembolism",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"5\">",
"       ICH",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Not receiving warfarin",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Receiving warfarin",
"      </td>",
"      <td class=\"subtitle2\" rowspan=\"2\">",
"       Difference in rate of thromboembolism&bull;",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Not receiving warfarin",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Receiving warfarin",
"      </td>",
"      <td class=\"subtitle2\" rowspan=\"2\">",
"       Difference in rate of ICH&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3\">",
"       Person, years",
"      </td>",
"      <td class=\"subtitle3\">",
"       Annual rate per 100 person, years",
"      </td>",
"      <td class=\"subtitle3\">",
"       Person, years",
"      </td>",
"      <td class=\"subtitle3\">",
"       Annual rate per 100 person, years",
"      </td>",
"      <td class=\"subtitle3\">",
"       Person, years",
"      </td>",
"      <td class=\"subtitle3\">",
"       Annual rate per 100 person, years",
"      </td>",
"      <td class=\"subtitle3\">",
"       Person, years",
"      </td>",
"      <td class=\"subtitle3\">",
"       Annual rate per 100 person, years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"11\">",
"       CHADS",
"       <sub>",
"        2",
"       </sub>",
"       score",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       0",
"      </td>",
"      <td>",
"       6143",
"      </td>",
"      <td>",
"       0.37",
"      </td>",
"      <td>",
"       3414",
"      </td>",
"      <td>",
"       0.38",
"      </td>",
"      <td>",
"       -0.01",
"      </td>",
"      <td>",
"       6133",
"      </td>",
"      <td>",
"       0.05",
"      </td>",
"      <td>",
"       3413",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       0.07",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1",
"      </td>",
"      <td>",
"       10,262",
"      </td>",
"      <td>",
"       1.19",
"      </td>",
"      <td>",
"       9083",
"      </td>",
"      <td>",
"       0.59",
"      </td>",
"      <td>",
"       0.59",
"      </td>",
"      <td>",
"       10,191",
"      </td>",
"      <td>",
"       0.22",
"      </td>",
"      <td>",
"       9082",
"      </td>",
"      <td>",
"       0.48",
"      </td>",
"      <td>",
"       0.27",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2",
"      </td>",
"      <td>",
"       9741",
"      </td>",
"      <td>",
"       2.54",
"      </td>",
"      <td>",
"       10,810",
"      </td>",
"      <td>",
"       1.26",
"      </td>",
"      <td>",
"       1.28",
"      </td>",
"      <td>",
"       9677",
"      </td>",
"      <td>",
"       0.40",
"      </td>",
"      <td>",
"       10,897",
"      </td>",
"      <td>",
"       0.61",
"      </td>",
"      <td>",
"       0.20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3",
"      </td>",
"      <td>",
"       4761",
"      </td>",
"      <td>",
"       3.89",
"      </td>",
"      <td>",
"       5965",
"      </td>",
"      <td>",
"       1.86",
"      </td>",
"      <td>",
"       2.03",
"      </td>",
"      <td>",
"       4835",
"      </td>",
"      <td>",
"       0.64",
"      </td>",
"      <td>",
"       6236",
"      </td>",
"      <td>",
"       0.61",
"      </td>",
"      <td>",
"       -0.03",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4-6",
"      </td>",
"      <td>",
"       1704",
"      </td>",
"      <td>",
"       6.34",
"      </td>",
"      <td>",
"       2857",
"      </td>",
"      <td>",
"       3.25",
"      </td>",
"      <td>",
"       3.08",
"      </td>",
"      <td>",
"       2158",
"      </td>",
"      <td>",
"       0.51",
"      </td>",
"      <td>",
"       3787",
"      </td>",
"      <td>",
"       1.08",
"      </td>",
"      <td>",
"       0.57",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CHADS",
"     <sub>",
"      2",
"     </sub>",
"     : congestive heart failure/hypertension/age/diabetes/prior stroke; HF: heart failure; ICH: intracranial hemorrhage.",
"     <br>",
"      * For all rates and rate differences, except those for CHADS",
"      <sub>",
"       2",
"      </sub>",
"      , strata are adjusted to account for the effects of the remaining risk factors listed in this table plus coronary artery disease (see Methods section). The rates presented for CHADS",
"      <sub>",
"       2",
"      </sub>",
"      are stratum-specific crude rates (that is, they are not adjusted further because the strata themselves are based on multivariable models).",
"      <br>",
"       &bull; Difference in rate of thromboembolism is calculated as (thromboembolism rate",
"       <sub>",
"        off warfarin",
"       </sub>",
"       ) - (thromboembolism rate",
"       <sub>",
"        on warfarin",
"       </sub>",
"       ). Difference in rate of ICH is calculated as (ICH rate",
"       <sub>",
"        on warfarin",
"       </sub>",
"       ) - (ICH rate",
"       <sub>",
"        off warfarin",
"       </sub>",
"       ).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151:297.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14957=[""].join("\n");
var outline_f14_38_14957=null;
var title_f14_38_14958="ASO hybridization and dot blot";
var content_f14_38_14958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Allele specific oligonucleotide (ASO) hybridization and dot-blot analysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 263px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This representation of ASO hybridization with dot blot analysis shows how this technique can be used to distinguish between an individual who is homozygous for a normal gene from individuals homozygous or heterozygous for a mutation in this gene. Patient DNA is red, and probes are green. In this case a normal gene is detected by a probe with the normal sequence, and a mutant gene is detected by a probe with a mutant sequence. The point mutation is denoted by an \"X\".",
"    <br/>",
"    Box 1: the normal probe is hybridized to spots of DNA \"dotted\" from a normal individual, an individual homozygous for the mutation, and an individual heterozygous for the mutation. The probe gives a signal for the normal and heterozygous individuals, but not the homozygous individual (who lacks the normal gene).",
"    <br/>",
"    Box 2: the mutant probe is hybridized to spots of DNA \"dotted\" from a normal individual, an individual homozygous for the mutation, and an individual heterozygous for the mutation. The probe gives a signal for the homozygous and heterozygous individuals but not the normal individual (who lacks the mutant gene).",
"    <div class=\"footnotes\">",
"     ASO: allele specific oligonucleotide.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14958=[""].join("\n");
var outline_f14_38_14958=null;
var title_f14_38_14959="Radioautography bands PCN pneumococci";
var content_f14_38_14959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radioautography enzyme bands for penicillin susceptibility among pneumococci",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 198px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Five distinct bands, each representing a different enzyme, are detected after incubation with penicillin-susceptible pneumococci. Reduced or absent labeling of one or more of the five bands results when strains have reduced susceptibility to penicillin. Labeling can generally be restored after incubation with higher penicillin concentrations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Markiewicz, Z, Tomasz, A. Variation in penicillin- binding protein patterns of penicillin-resistant clinical isolates of pneumococci. J Clin Microbiol 1989; 27:405. Copyright &copy; 1989 American Society for Microbiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_38_14959=[""].join("\n");
var outline_f14_38_14959=null;
